FLT3 and acute myeloid leukemia: Venetoclax is now on study with conventional chemotherapy (NCT03709758), as well with other multi-targeted combinations (e.g., FLT3 inhibitors or glasdegib- NCT03625505 and NCT03735875) to overcome AML resistance and apply a better personalized pharmacologic approach [71].